BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 week ago
Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme - News-Medical.Net, 1 month ago
One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis - TickerTech.com, 1 month ago
3 images for "Tecfidera Treated Patients"
News Categories Clinical Trials Research News Industry Trends AgencyPharmscope, 1 week ago
[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...World Socialist Web Site, 3 weeks ago Obamacare shortchanges patients with chronic disease American Enterprise Institute, 1 month ago Under Obamacare's "Closed Formularies" Patients With Serious Diseases Don't Get Access to Vital And Very Costly Medicines Forbes.com, 1 month ago
/CNW/ - Biogen Idec Canada announces today that TECFIDERA (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERA is a first-line oral treatment for adults with relapsing-remitting ...CEOWorld Magazine, 1 month ago
Introduction The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies.Pettinga Financial Advisors, 1 month ago
It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...Motley Fool, 1 week ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera FDA News, 2 weeks ago Biogen MS blockbuster Tecfidera earns high marks for safety FiercePharma, 1 month ago MS Drug Tecfidera More Trouble Than It's Worth? EMax Health, 1 month ago
More from: , Algarve Resident...and 1 other sources
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). The trial will assess the safety, tolerability ...Pharmaceutical Business Review, 1 week ago Alkermes takes its Tecfidera beater into clinical trials for MS FierceBiotech, 2 weeks ago
UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) today for US biotech firm Biogen Idec's (Nasdaq: BIIB) new oral multiple sclerosis (MS) drug Tecfidera ...Pharma Letter, 2 weeks ago
The new MS pill Tecfidera (also known as dimethyl fumarate) has received the final stamp of approval from NICE, and should now be freely available on the NHS in England and Wales to people with active relapsing remitting MS. After an initial ...Noodls, 2 weeks ago
Mergers and acquisitions (M&As) continue to play a major role in the pharma sector and are not showing any signs of slowing down. The last few months have brought tax inversion deals into focus considering the number of agreements signed with ...Zacks.com, 1 week ago Pharma, Biotech M&As Heat Up: Tax Inversion in Focus Yahoo! Finance, 1 week ago
on your WebpageAdd Widget >Get your members hooked!